Combined intervention of exercise and genistein prevented androgen deficiency-induced bone loss in mice

JIAN WU,1 XIN XIANG WANG,1 HIROSHIGE CHIBA,1 MISAO TAKASAKI,1 ATSUTANE OHTA,1 AND YOSHIKO ISHIMI1

1Division of Food Science, and 2Division of Health Promotion, National Institute of Health and Nutrition, Tokyo 162–8636, Japan; and 3Nutritional Science Center, Bioscience Laboratories, Meiji Seika Kaisha, Saitama 350-0298, Japan

Submitted 6 June 2002; accepted in final form 19 September 2002

Wu, Jian, Xin Xiang Wang, Hiroshiige Chiba, Mitsuru Takasaki, Atsutane Ohta, and Yoshiko Ishimi. Combined intervention of exercise and genistein prevented androgen deficiency-induced bone loss in mice. J Appl Physiol 94: 335–342, 2003; 10.1152/japplphysiol.00498.2002.—There is evidence that estrogen plays an important role in skeletal tissue in males as well as females. We have reported that phytoestrogens, such as genistein, selectively act on bone and exhibit cooperative effects on bone mass when combined with exercise in ovariectomized mice. In this study, we examined whether both interventions exhibit cooperative effects on bone loss in androgen-deficient mice similar to those in estrogen-deficient mice. Male mice aged 7 wk were either sham operated or orchidectomized (ORX) and divided into six groups: 1) sham; 2) ORX; 3) ORX and treated with genistein (0.4 mg/day) subcutaneously; 4) ORX, exercised on a treadmill daily for 30 min/day at 12 m/min; 5) ORX, given genistein, and exercised (ORX+ExG); and 6) ORX and treated with 17β-estradiol (E2). Four weeks after the intervention, seminal vesicle weight strikingly decreased in ORX mice, and it was not affected by administration of genistein or E2. Bone mineral density of whole femur was significantly reduced by ORX, and bone loss was prevented by the combined intervention. Histomorphometric analysis showed that bone volume and trabecular thickness in the distal femoral cancellous bone were significantly lower in the ORX group than in the Sham group, and they were completely restored in the ORX+ExG group, as in the ORX with E2 group. These results indicate that the combined intervention of moderate exercise and a low dose of genistein administration shows an additive effect in preventing bone loss in ORX mice similar to that in ovariectomized mice.

osteoporosis

ADDRESS FOR REPRINT REQUESTS AND OTHER CORRESPONDENCE: Y. Ishimi, Division of Food Science, National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8636 Japan (E-mail: ishim@nih.go.jp).


http://www.jap.org 8750-7587/03 $5.00 Copyright © 2003 the American Physiological Society

335
and genistein administration on the bone mass in androgen-deficient mice to examine whether both treatments exhibit cooperative effects similar to those in estrogen-deficient mice.

MATERIALS AND METHODS

Animal and intervention. Seven-week-old male mice of the ddY strain were purchased from the Shizuoka Laboratory Animal Center (Shizuoka, Japan) and fed an AIN-95G diet with corn oil instead of soybean oil (Funabashi Farm, Chiba, Japan) (30). The mice were individually housed in 24 × 15 × 15-cm cages under a 12:12-h light-dark cycle at 22°C and were allowed free access to water and diet. Both genistein (Fujicco, Kobe, Japan) and 17β-estradiol (E2; Sigma Chemical, St. Louis, MO) were dissolved in 20% dimethyl sulfoxide in polyethylenglycol-300 and were administered to the mice subcutaneously by using a miniosmotic pump (model 2002; Alza, Palo Alto, CA) immediately after surgery. Before the combined intervention of genistein and moderate exercise on bone mass in orchidectomized (ORX) mice were studied, the dose-dependent effect of genistein on bone was examined. Twenty-four mice were either sham operated (Sham; n = 61) or ORX (n = 18). ORX mice were subcutaneously treated with 0.4 mg/day (ORX-0.4G) or 0.8 mg/day (ORX-0.8G) of genistein or vehicle solution (ORX-Cont) for 3 wk. When the cooperative effects of combination of genistein and exercise on bone mass were examined, 48 mice were either Sham (n = 8) or ORX. Furthermore, ORX mice were randomly divided into five groups: ORX (ORX, n = 8); genistein administration (ORX+G, n = 8); exercise training (ORX+Ex, n = 8); combined genistein and exercise (ORX+ExG, n = 8); and E2 administration (ORX+E2, n = 8). Four weeks after the start of intervention, the mice were killed, and the seminal vesicle weight was measured. Both femora were also removed to analyze bone mineral density (BMD) and structure. Genistein was given at a low dose (0.4 mg/day), and E2 was treated at 0.03 μg/day by using the miniosmotic pump mentioned above. The exercise regimen consisted of daily running on a treadmill (Natsume, Tokyo, Japan) for 30 min/day at 12 m/min at a 10° upward slope. All procedures were performed in accordance with the National Institutes of Health and Nutrition Guidelines for the Care and Use of Laboratory Animals.

Radiographic analysis. Radiographic analysis of the femur was performed by using a soft X-ray system (model SRO-M50; SOFIRON, Tokyo, Japan). Bone mineral content (BMC) and BMD of the femur were measured by dual-energy X-ray absorptiometry (DXA) by using a bone densitometer adapted for small animal research (model DCS-600R; Aloka, Tokyo, Japan). BMC of the mouse femora was closely correlated with the ash weight (r = 0.978) (19). BMD was calculated by BMC of the measured area. The scanned area of the femur was equally divided into three regions (proximal femur, midshaft, and distal femur; 5.3 mm each) to assess the regional differences in the femur.

Peripheral quantitative computed tomography analysis. The femora were scanned with a peripheral quantitative computed tomography (pQCT) system XCT Research SA combined with μScope (Norland Stratec Medizintechnik GmbH, Birkenfeld, Germany). The voxel size was 0.08 mm, the slice thickness was 0.5 mm, and the cortical threshold was 464 mg/cm³. We employed the Peel mode 20 measuring mode for dividing into cortical bone or trabecular bone. This mode can detect the inner threshold automatically. One cross-sectional slice from each femora was scanned at the midshaft, 8 mm from the distal end, which was determined from a scout view of the pQCT device. Cortical mineral content and density at the midshaft were analyzed for each slice. Total cross-sectional area (CSA) and periosteal perimeter (Peri) were also evaluated by the scanning.

Histomorphometric analysis. The left femur was fixed in 70% ethanol, and the decalcified bone was embedded in glycol methacrylate. A 3-μm-thick section was cut longitudinally in the distal region of the femora and was stained for tartrate-resistant acid phosphatase. Histomorphometry was performed with the semiautomatic image analyzing system (Osteoplan; Carl Zeiss, Thornwood, NY) linked to a light microscope (18). The histomorphometric measurements were made at ×200 magnification by using a minimum of 10 optical fields in the secondary spongiosa area from the growth plate-metaphyseal junction. All sections were examined blind. Nomenclature, symbols, and units that were used are those recommended by the Nomenclature Committee of the American Society for Bone and Mineral Research (27).

Statistical analysis. Data are presented as means ± SE. Significance of differences was determined by one-way ANOVA followed by Fisher’s protected least-significant difference test. The effect of the intervention, running exercises, and interaction of both interventions were analyzed by two-way ANOVA. Significance of differences was determined by Fisher’s protected least-significant difference test. Differences were considered significant at the level of P < 0.05.

RESULTS

Dose-response of genistein on BMD in ORX mice. To examine the dose-dependent effect of genistein on BMD, ORX mice were treated for 3 wk with 0.4 or 0.8 mg/day of genistein, and BMD of the femora were measured. Distal and whole femoral BMD were significantly reduced by ORX, and administration of genistein significantly suppressed this reduction in a dose-dependent manner (Table 1). Genistein at 0.4 mg/day has been defined as a minimal dose sufficient for a bone-protective effect in ORX mice.

Cooperative effects of genistein and exercise on bone mass in ORX mice. There were no significant differences in body weight among sham-operated mice, ORX mice, and ORX mice treated with genistein with or without exercise intervention during a 4-wk experimental period. The lower body weight in the ORX groups com-

Table 1. Dose-dependent effect of genistein on BMD at distal and whole femora in ORX mice

<table>
<thead>
<tr>
<th>Group</th>
<th>BMD, mg/cm²</th>
<th>Distal</th>
<th>Whole</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>40.8 ± 0.5</td>
<td>38.1 ± 0.4</td>
<td></td>
</tr>
<tr>
<td>ORX-Cont</td>
<td>33.9 ± 0.6*</td>
<td>34.3 ± 0.7*</td>
<td></td>
</tr>
<tr>
<td>ORX-0.4G</td>
<td>36.2 ± 0.7*</td>
<td>34.9 ± 0.5*</td>
<td></td>
</tr>
<tr>
<td>ORX-0.8G</td>
<td>38.0 ± 0.4†</td>
<td>36.5 ± 0.4†</td>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SE of 8 mice. Bone mineral density (BMD) of the distal and whole femora were measured at 3 wk after the operation by dual energy X-ray absorptiometry. Mice were sham operated (Sham) or orchidectomized (ORX), and ORX mice were treated with 0.4 mg/day (ORX-0.4G) or 0.8 mg/day (ORX-0.8G) of genistein. *Significantly different from Sham group. †Significantly different from ORX-Cont (ORX + treated with vehicle solution) group. All differences were analyzed by multiple comparison with one-way ANOVA (P < 0.05).
pared with the Sham group might be due to extirpation of the testicles (Fig. 1A). Seminal vesicle weight strikingly decreased in ORX mice, which indicated that the mice were androgen deficient. Administration of genistein for 4 wk at 0.4 mg/day did not affect seminal vesicle weight in ORX mice. The combination of genistein administration and running exercise or E2 treatment also did not affect seminal vesicle weight (Fig. 1B).

**Bone mass and structural properties.** Figure 2A shows radiograms of the femora collected from mice in each group. X-ray analysis revealed that the mineralized cancellous bone mass in ORX mice had significantly decreased, especially in the distal metaphysis of the femur. Combined intervention of genistein administration and running exercise or E2 administration markedly prevented bone loss.

During DXA analysis, whole femoral BMD was significantly reduced by ORX. The decrease in BMD was significantly inhibited by the combined intervention of exercise and 0.4 mg/day of genistein administration, although it was not affected by either intervention alone (Fig. 2B). The bone area of the whole femur in the ORX+Ex and ORX+ExG groups was significantly larger than that in the other groups (Fig. 2C). To evaluate a site-specific effect of genistein and/or exercise intervention, femoral BMD and area were further analyzed at the proximal, middle, and distal regions of the femur (Table 2). ORX reduced BMD in the proximal, middle, and distal regions of the Sham mice by 5.7, 9.4, and 8.6%, respectively. The combined intervention of genistein and exercise completely prevented bone loss at the proximal and distal regions in ORX mice. However, BMD in the middle region was not affected by the combined intervention. Exercise partially inhibited ORX-induced bone loss in the distal region. E2 treatment completely prevented the decrease in BMD in all three regions. Bone area was markedly higher in both the exercise and combined intervention groups compared with those in the other ORX and Sham groups at the distal region.

The results of densitometric evaluation by pQCT are shown in Fig. 3. Both cortical BMD and BMC at the femoral midshaft, 8 mm from the distal end, were reduced in the ORX mice compared with Sham mice. Either genistein or exercise alone and combined intervention did not affect BMD and BMC in ORX mice. Neither CSA nor Peri at the midshaft was affected by either intervention alone or by the combined intervention in ORX mice. These results in the analysis by pQCT were well correlated to those evaluated by DXA in the middle region of the femur.

**Histological analysis.** To define the effects of genistein administration and running exercise on the trabecular bone, histological sections of distal femoral metaphysis were prepared, and bone volume-to-tissue volume ratio (BV/TV), Tb.Th, and Tb.Sp were evaluated (Fig. 4). BV/TV and Tb.Th were markedly decreased by ORX, however, these were significantly recovered by combined intervention. Although either genistein administration or running exercise partially prevented decreased BV/TV and Tb.Th, a two-factor ANOVA showed the effects of exercise and genistein intervention, and their interactions on histological parameters were not significant. Tb.Sp was dramatically increased in ORX mice, whereas combined intervention completely protected the separation, as did E2.

**DISCUSSION**

The present study demonstrates that the combined intervention of moderate exercise and low-dose genistein administration shows an additive effect in preventing bone loss, especially in the femoral cancellous bone by inhibiting bone resorption in ORX mice. These results are consistent with our previous findings showing the protective effects of the combination of genistein administration with running exercise on bone loss in OVX mice (35). However, unlike OVX mice, cortical BMD, the periosteum perimeter and CSA at
the midshaft of the femur, was not affected by exercise or combined intervention in ORX mice.

Clinical hypogonadism is a well-established cause of osteoporosis in men. It has been reported that an androgen deficiency caused by ORX results in bone loss as a result of stimulating bone resorption in experimental animals (9, 23). Erben et al. (6) have reported that ORX not only reduces the serum levels of total and free testosterone but also the level of E₂. They also showed that E₂ was the only significant predictor of histomorphometric indexes of bone formation and resorption in ORX rats. Furthermore, because it has been reported that a mutated estrogen receptor or aromatase deficiency in men can result in osteoporosis, the role of estrogen in the male skeleton has received considerable attention (5, 21, 32). In fact, in this study, bone loss induced by castration was prevented by estrogen treatment, as previously reported (23, 24). On the basis of these findings, natural dietary plant estrogens such as isoflavones, particularly those found in soy products, seem to be potential alternatives to estrogens (2, 12, 13). Recently, we reported that administration of 0.7–0.8 mg/day of genistein markedly prevented bone loss caused by either estrogen or androgen deficiency without substantial effects on the reproductive tissues in osteoporotic animal models (12–14). We also found that administration of a submaximal dose of genistein (0.4 mg/day) partially but significantly prevented the decrease in BMD of the femora in OVX mice (13, 35). Although the decrease in femoral BMD caused by ORX was not significantly affected by administration of a low dose of genistein (0.4 mg/day), the high

Table 2. Effects of exercise, genistein, and combined interventions on BMD and bone area of femora in ORX mice

<table>
<thead>
<tr>
<th></th>
<th>BMD, mg/cm²</th>
<th>Area, cm²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Proximal</td>
<td>Midshaft</td>
</tr>
<tr>
<td>Sham</td>
<td>43.8 ± 0.4</td>
<td>37.1 ± 0.6</td>
</tr>
<tr>
<td>ORX</td>
<td>41.3 ± 0.6*</td>
<td>33.6 ± 0.9*</td>
</tr>
<tr>
<td>ORX + G</td>
<td>41.2 ± 0.7*</td>
<td>33.1 ± 1.0*</td>
</tr>
<tr>
<td>ORX + Ex</td>
<td>43.0 ± 0.4</td>
<td>33.1 ± 0.8*</td>
</tr>
<tr>
<td>ORX + ExG</td>
<td>44.2 ± 0.7b</td>
<td>34.1 ± 0.3*</td>
</tr>
<tr>
<td>ORX + E₂</td>
<td>44.5 ± 1.3b</td>
<td>40.1 ± 1.3b</td>
</tr>
</tbody>
</table>

Values are means ± SE of 8 mice. BMD and bone area at the proximal region, midshaft, and distal region of the excised femora were measured by dual X-ray absorptiometry 4 wk after the operation. Mice were sham operated or ORX, and some ORX mice were treated with 0.4 mg/day of genistein (ORX + G), trained to exercise (ORX + Ex) or treated with 0.03 μg/day of 17β-estradiol (ORX + E₂). Significantly different from Sham group. Significantly different from ORX group. Significantly different from ORX + G group. Significantly different from ORX + Ex group. Significantly different from ORX + ExG group. All differences were analyzed by multiple comparison with one-way ANOVA (P < 0.05).
dose at 0.8 mg/day significantly protected bone loss in ORX mice. These results suggest that intake of isoflavones would be beneficial to maintain bone mass in males with hypogonadism.

Exercise has been reported to prevent bone loss induced by gonadectomy in both sexes (15, 28, 36–38). We reported that moderate running exercise significantly prevented bone loss and increased the bone area.
of the femur in OVX mice (35). In the present study, we found that running exercise, at the same intensity as in trained OVX mice, significantly increased the bone area and partially prevented bone loss at the distal femur in ORX mice (Table 2). We also reported that running exercise improved the structural parameters and bone formation rate at the midshaft of the femur in OVX mice. However, in ORX mice, the running exercise had no effect on BMD, CSA, and Peri at the midfemur (Fig. 3). These findings are consistent with the observation that running exercise had no significant effect on diaphyseal BMD (mainly cortical), whereas it increased metaphyseal BMD (predominantly cancellous) in young ORX rats (10). Therefore, it is considered that running exercise prevents bone loss mainly by the inhibition of bone resorption but not by the stimulation of bone formation under androgen-deficient conditions, especially in growing and young animals. In other words, androgen might be necessary to respond to the mechanical stress at the cortical bone in male mice. This hypothesis is also supported by the data of Horcajada-Molteni et al. (11). They reported that treadmill running exercise was able to prevent bone loss induced by ORX, mainly by inhibiting bone resorption without affecting osteoblastic activity.

It has been suggested that the effect of running exercise on augmentation of bone was site specific. In this study, we found that the running exercise increased bone area in the distal region, which may lead to an increase in bone area of whole femur, but not in proximal and middle regions evaluated by DXA. We also found that CSA and Peri at the femoral midshaft analyzed by pQCT did not differ between exercised and nonexercised animals. Iwamoto et al. (16) reported that growing rats subjected to treadmill exercise showed greater increases in bone volume at the distal tibia compared with the proximal tibia. One putative explanation is that the most distal aspects of the limb are in closer contact with the ground and are thus loaded more directly. A second compelling explanation is that interstitial fluid pressure, which is created by gravitational force from top to bottom of the body, regulates bone mass (33). This would suggest that an exercise of the lower extremities done while standing upright, such as erect bipedal standing or jumping, will be more effective in augmenting bone mass than exercise done while running in a four-footed animal. Yao et al. (36) have reported that exercise by making ORX rats rise to an erect bipedal stance partially prevented cancellous and cortical bone loss in tibiae induced by ORX. These results differ somewhat from the present study and previous reports that found that treadmill exercise had a beneficial effect on cancellous bone but not on cortical bone. Consequently, it appears that mechanical loading was greater in bipedal resistance stance than in running exercise by all four limbs. In fact, the magnitude of loading is more effective than the number of cycles for stimulating bone formation reported by human and animal studies (34).

When ORX mice were treated with the combination of genistein administration and running exercise, the decrease in BMD was completely prevented at the proximal and distal femoral regions by analyzing DXA measurements (Table 2). Similar to effects seen in OVX mice, the combined intervention also exhibited significant effects on BV/TV and Tb.Sp in the distal femoral metaphysis in the histomorphometric analysis in ORX mice. Two-way ANOVA revealed that there was no synergistic interaction between genistein administration and exercise, and this supports the idea that the beneficial effects were the result of the additive effects of the two independent factors. On the other hand, we did not find the efficacy of the combined intervention on the bone mass, CSA, and Peri at the midfemur measured by DXA and pQCT in ORX mice (Fig. 3). In fact, there were no differences in these parameters between the ORX group and any of the treatment groups alone. However, in OVX mice, we found that this combined intervention not only completely restored the bone mass to the sham level, but also increased the bone area, Peri, and bone formation rate at the diaphysis of the midfemur (35). ORX reduced periosteal appositional growth in cortical bone in growing male rats and can be reversed by androgen replacement (29). Thus, this evidence suggests that androgens are important for bone formation on cortical bone in male animals. This may explain the different response of the cortical bone at the midfemur to combined intervention in ORX and OVX mice.

The mechanism of interaction between running exercise and genistein administration in bone metabolism under androgen-deficient conditions is not clear. It has been suggested that androgen regulates bone metabolism after conversion to estrogen by aromatase in males (5, 21). In fact, in the aromatase-deficient mice, a marked loss of cancellous bone due to increased bone resorption was observed not only in females but also in young males (20, 26). These findings indicate that estrogen has crucial roles in bone metabolism in males. It has been suggested that estrogen may tend to lower the set points of bone modeling and remodeling thresholds in females (8). In the present study, we found that combined intervention exhibited a beneficial effect on trabecular bone, but not cortical bone, in ORX mice. Therefore, it is likely that the signals of phytoestrogen influence the set point of trabecular bone that is regulated mainly by estrogen even in ORX mice. Further studies are necessary to explain this point. Furthermore, it is important to examine whether the combined intervention could prevent bone loss attributed to androgen deficiency in men. If so, it may be useful to establish a clinical treatment regimen for the prevention of osteoporosis.

In conclusion, we demonstrated that the combined intervention of moderate running exercise and an administration of low-dose genistein showed an additive effect in preventing bone loss, especially at the trabecular bone of the distal metaphysis in ORX mice similar to that in OVX mice. These results suggested that combined dietary natural phytoestrogens such as genistein with moderate exercise might be useful for the prevention of
osteoarthritis not only in postmenopausal women but also in elderly men with hypogonadism.

We thank Drs. Chisato Miyaura (Tokyo University of Pharmacy and Life Science), Tomio Morohashi (Showa University), Hideyuki Yamato, and Hisashi Murayama (Hard Tissue Research Team, Kueha Chemical Industry) for assistance with DXA, pQCT, and histological analyses, respectively. This work was supported by a Science and Technology Agency Fellowship Award and by Grant-in-Aid 13860175 from the Ministry of Science, Education, and Culture of Japan.

REFERENCES


